NCT03221426 2026-03-09
KEYNOTE-585
Merck Sharp & Dohme LLC
Phase 3 Completed
Clinical Trials
54 trialsNCT05567835 2026-02-23
TOGAR
Baylor College of Medicine
Phase 2 Terminated
NCT04306900 2025-07-29
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
Trishula Therapeutics, Inc.
Phase 1 Completed
NCT05461794 2025-06-13
Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma
BeiGene
Phase 2 Terminated
NCT02485834 2025-01-20
FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
NCT01905150 2024-12-11
Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer
Bruckner Oncology
Phase 2 Completed
NCT03430843 2024-10-26
A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
BeiGene
Phase 3 Completed
NCT02735239 2024-03-22
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT03099382 2024-01-22
Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT01515748 2023-12-13
PRODIGY
Sanofi
Phase 3 Completed
NCT02324543 2023-07-21
Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT00042939 2023-07-06
Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00551759 2023-07-03
Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT03933449 2023-03-29
KEYNOTE-181
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02564263 2023-03-13
KEYNOTE-181
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02569242 2022-07-06
Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer
Ono Pharmaceutical Co. Ltd
Phase 3 Completed
NCT00193128 2021-11-24
Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer
SCRI Development Innovations, LLC
Phase 1/2 Completed
NCT04165031 2021-11-24
A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation
Eli Lilly and Company
Phase 1/2 Terminated
NCT01459614 2021-05-19
Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT01217060 2021-04-13
Trimodality Management of T1b Esophageal Cancers
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00066677 2021-03-05
Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
Fox Chase Cancer Center
Phase 2 Terminated
NCT00446290 2020-01-18
Study of Docetaxel, Capecitabine and Oxaliplatin in Advanced Stomach Cancer
Asan Medical Center
Phase 1 Completed
NCT00515411 2019-12-10
Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01498289 2019-11-07
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT00217581 2019-03-26
Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT01715233 2019-03-15
Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00711243 2019-02-26
Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor
Northwestern University
Phase 1/2 Completed
NCT00276744 2018-10-24
Individualized Drug Treatment for Treating Patients With Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT02358863 2018-09-06
mEGA
Georgetown University
Phase NA Terminated
NCT00183872 2018-02-19
Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma
University of Southern California
Phase 2 Completed
NCT00426127 2017-12-29
Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic Cancer
University of Iowa
Phase 2 Terminated
NCT00290693 2017-12-02
Capecitabine and Docetaxel in Treating Patients With Recurrent or Progressive Metastatic Pancreatic Cancer
University of Miami
Phase 2 Completed
NCT00833859 2017-10-09
Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00394433 2017-08-01
Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00609336 2017-07-13
Perioperative Therapy for Resectable Pancreatic Cancer
University of Washington
Phase 2 Completed
NCT00448682 2017-02-07
Combination Chemotherapy as First-Line Therapy in Treating Patients With Stage IV Gastric Cancer That Cannot Be Removed By Surgery
University of Miami
Phase 2 Terminated
NCT00448760 2017-02-07
Combination Chemotherapy in Treating Patients With Previously Untreated Stage II or Stage III Esophageal Cancer That Can Be Removed By Surgery
University of Miami
Phase 2 Completed
NCT00517829 2016-11-28
Docetaxel+Oxali+/-Cetux Met Gastric/GEJ
US Oncology Research
Phase 2 Completed
NCT00526110 2016-10-31
Docetaxel, 5-Fluorouracil and Oxaliplatin in Adenocarcinoma of the Stomach or Gastroesophageal Junction Patients
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00454636 2016-09-29
A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer.
Hoffmann-La Roche
Phase 2 Completed
NCT00882310 2016-07-25
A Study of Gemzar, Taxotere, and Xeloda for Adjuvant Pancreatic Cancer
Columbia University
Phase 2 Completed
NCT00996333 2016-07-25
Study of Gemzar®, Taxotere®, and Xeloda® (GTX) in Patients With Metastatic Pancreatic Cancer (Stage IVB)
Columbia University
Phase 2 Completed
NCT00320749 2016-06-27
Capecitabine, Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT00869258 2016-06-22
Study for Inoperable Non-Metastatic Pancreatic CA (Stage IVA) With Neoadjuvant GTX, and Radiation With Gemzar
Columbia University
Phase 2 Completed
NCT01129206 2016-06-01
Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT00868998 2016-05-23
GTX Regimen for Biliary Cancers
Columbia University
Phase 2 Terminated
NCT00390416 2016-03-14
Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00757172 2016-03-11
Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00532441 2016-02-12
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Hoosier Cancer Research Network
Phase 2 Terminated
NCT00737438 2016-02-03
Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed